Insider · CIK 0002119354
Kevin Puylaert
Files at SOPH (SOPHiA GENETICS SA). First filing Mar 20, 2026, latest Oct 7, 2026.
In brief
Kevin Puylaert files SEC Form 4 as officer at SOPH (SOPHiA GENETICS SA). Since Mar 20, 2026, Kevin Puylaert has reported 0 open-market buys worth $0 and 7 open-market sells worth $6,344, the latest filed on Oct 7, 2026.
A track record needs three past buys with six months of prices behind them; Kevin Puylaert has 0, so none is measured yet.
The newest scored trade: sold $1,737 of SOPH on Oct 5, 2026, filed Oct 7, 2026, scored 30 (weak). In the last 12 months: 0 buys worth $0 and 7 sells worth $6,344.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SOPH: SOPHiA GENETICS SA
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | SOPHiA GENETICS SA | $1,737 216 shares | -0% | +111% from low-8% from high | |
| 30Weak | SOPHiA GENETICS SA | $1,087 216 shares | -0% | +77% from low-11% from high | |
| 30Weak | SOPHiA GENETICS SA | $150 33 shares | -0% | +64% from low-15% from high | |
| 30Weak | SOPHiA GENETICS SA | $168 33 shares | -0% | +87% from low-6% from high | |
| 30Weak | SOPHiA GENETICS SA | $3,032 624 shares | -0% | +86% from low-10% from high | |
| 30Weak | SOPHiA GENETICS SA | $14 3 shares | -0% | +86% from low-10% from high | |
| 30Weak | SOPHiA GENETICS SA | $157 33 shares | -0% | +83% from low-12% from high |
Transactions
Every row this insider has filed, 16 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 5, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares | -185 | $8.06 | $1,491 | 147,763 | 8 d ago |
| Oct 5, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares | -31 | $7.92 | $246 | 147,732 | 8 d ago |
| Jul 6, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares | -138 | $5.03 | $693 | 148,026 | Jul 7, 2026 |
| Jul 6, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares | -47 | $5.03 | $236 | 147,979 | Jul 7, 2026 |
| Jul 6, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares | -31 | $5.09 | $158 | 147,948 | Jul 7, 2026 |
| May 19, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares | -33 | $4.54 | $150 | 148,164 | May 20, 2026 |
| Apr 20, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares | -33 | $5.08 | $168 | 148,197 | Apr 21, 2026 |
| Apr 6, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares | -548 | $4.86 | $2,663 | 148,306 | Apr 8, 2026 |
| Apr 2, 2026 | SOPH SOPHiA GENETICS SA | AGrant or award Ordinary Shares | +56,468 | $0.00 | $0 | 148,854 | Apr 8, 2026 |
| Apr 6, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares | -46 | $4.86 | $224 | 148,260 | Apr 8, 2026 |
| Apr 2, 2026 | SOPH SOPHiA GENETICS SA | AGrant or award Share Option (Right to Buy)derivative | +82,335 | $0.00 | $0 | 82,335 | Apr 8, 2026 |
| Apr 6, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares | -30 | $4.83 | $145 | 148,230 | Apr 8, 2026 |
| Apr 2, 2026 | SOPH SOPHiA GENETICS SA | AGrant or award Ordinary Shares | +56,468 | $0.00 | $0 | 56,468 | Apr 3, 2026 |
| Apr 2, 2026 | SOPH SOPHiA GENETICS SA | AGrant or award Share Option (Right to Buy)derivative | +82,335 | $0.00 | $0 | 82,335 | Apr 3, 2026 |
| Mar 31, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares | -3 | $4.71 | $14 | 92,383 | Apr 1, 2026 |
| Mar 19, 2026 | SOPH SOPHiA GENETICS SA | SOpen-market sale Ordinary Shares | -33 | $4.76 | $157 | 92,386 | Mar 20, 2026 |
Questions about Kevin Puylaert
Answered from the filings on this page, as of the latest one.
Is Kevin Puylaert buying or selling?
In the last 12 months Kevin Puylaert reported 0 open-market buys worth $0 and 7 open-market sells worth $6,344 on SEC Form 4; the latest was sold $1,737 of SOPH on Oct 5, 2026. Grants, option exercises and tax withholding are not counted.
How did Kevin Puylaert's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Kevin Puylaert has 0.
Where does Kevin Puylaert file Form 4?
Kevin Puylaert has filed Form 4 at SOPH (SOPHiA GENETICS SA) as Chief Sales Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.